Cardiac Myosin Binding Protein-C Phosphorylation Mitigates Age-Related Cardiac Dysfunction: Hope for Better Aging?

Paola C Rosas1, Chad M Warren1, Heidi A Creed2

  • 1Department of Physiology and Biophysics, Center for Cardiovascular Research, College of Medicine, University of Illinois at Chicago, Chicago, Illinois.

Insights

Phosphorylating cardiac myosin binding protein-C (cMyBP-C) prevents age-related heart dysfunction. This study shows phosphorylated-mimetic cMyBP-C mice maintained better heart function and survival, suggesting a therapeutic target.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Aging Research

Background:

  • Aging leads to cardiac dysfunction, a significant health concern.
  • Cardiac myosin binding protein-C (cMyBP-C) is crucial for heart muscle contraction.
  • Phosphorylation of cMyBP-C is a potential regulator of cardiac function during aging.

Purpose of the Study:

  • To investigate whether cMyBP-C phosphorylation prevents aging-related cardiac dysfunction.
  • To determine the functional consequences of altered cMyBP-C phosphorylation in aging mouse models.

Main Methods:

  • Aging of genetic mouse models with hypophosphorylated, wild-type equivalent, and phosphorylated-mimetic cMyBP-C for 18-20 months.
  • Assessment of cardiac function, including systolic and diastolic parameters, and cardiac hypertrophy.
  • Intact papillary muscle experiments to elucidate the underlying molecular mechanisms.

Main Results:

  • Mice with phosphorylated-mimetic cMyBP-C showed improved survival, preserved systolic and diastolic functions, and stable wall thickness.
  • Wild-type equivalent mice exhibited decreased cMyBP-C phosphorylation with worsening cardiac function and hypertrophy.
  • Phosphorylation of cMyBP-C was linked to increased cross-bridge detachment rates.

Conclusions:

  • cMyBP-C phosphorylation is a key mechanism that prevents aging-related cardiac dysfunction.
  • Targeting cMyBP-C phosphorylation represents a novel therapeutic strategy for age-related heart disease.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
307
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
253
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.3K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
121.8K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
2.2K